Previous cancer genomic studies across lung adenocarcinoma (ADC) patients have revealed recurrent mutations in the splicing factor U2AF1 (Brooks et al, 2014; Cancer Genome Atlas Research Network, 2014; Campbell et al, 2016). This evidence concerns the gene U2AF1 and lung adenocarcinoma.